Objective: To evaluate clinical literature for direct oral anticoagulants (DOACs) therapy for
non–Food and Drug Administration approved indications. Data Sources: Articles from …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Direct oral anticoagulants have been an increasingly used class of drugs in the setting of
nonvalvular atrial fibrillation, defying vitamin K antagonists' monopoly when it comes to …

Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF), which, according to the American College of …

Direct oral anticoagulants (DOACs) are increasingly used in clinical practice and have
become essential in the management of atrial fibrillation and VTE. The enthusiasm for …

Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Direct oral anticoagulants (DOACs) are indicated by the European Medicines Agency and
US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …